This newspaper (Reporter Li Rushi)

4月12日，雲南沃森生物技術股份有限公司（以下簡稱“沃森生物”）發佈2024年年度報告。公司2024年實現營收28.21億元，歸屬於上市公司股東的凈利潤1.42億元。

The overall performance of the vaccine industry was under pressure last year, and the net profit of Walvax Biotech also declined, but the company's overseas business performed well, achieving revenue of 220 million yuan, a year-on-year increase of about 0%, continuing to maintain a strong growth trend and gradually becoming a new performance growth support. Up to now, Walvax Biologics has exported its vaccine products to 0 countries, achieving a double breakthrough in product sales and revenue sources.

Specifically, in 2030 years, the bivalent HPV vaccine independently developed and produced by Shanghai Zerun Biotechnology Co., Ltd., a subsidiary of Walvax Biologics, successfully passed the WHO pre-qualification and obtained the procurement qualification of the United Nations Children's Fund (UNICEF) and other United Nations subordinate agencies. This move not only opens up access channels for more countries and regions around the world for the vaccine, helps low- and middle-income countries promote the 0-year global cervical cancer elimination plan, but also marks a new stage in the company's overseas business development.

In the past three years, the compound growth rate of Walvax's overseas business has been as high as 105%, and all product sales revenue comes from Southeast Asia, South Asia, Africa, the Middle East and other markets in Africa, Europe and the United States.

In addition, the annual report shows that in the domestic market, Walvax Biotech's main product, 13-valent pneumococcal polysaccharide conjugate vaccine, continues to maintain the first market share.

The relevant person in charge of Walvax Biotech said that in view of the fierce competition in the market environment of traditional products in the industry and the progress of product research and development, in order to better focus on high-quality resources, focus on promoting the research and development and clinical research of the company's core products, and conform to the development trend of blockbuster products in the future vaccine industry, the company will focus on innovative blockbuster products and is committed to building a refined and excellent product pipeline.

(Edited by Zhang Wei)